American Century Companies Inc. Acquires Shares of 346,572 NewAmsterdam Pharma (NASDAQ:NAMS)

American Century Companies Inc. acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 346,572 shares of the company’s stock, valued at approximately $8,907,000. American Century Companies Inc. owned 0.38% of NewAmsterdam Pharma at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $80,000. Quarry LP lifted its holdings in shares of NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC grew its position in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after acquiring an additional 7,199 shares during the last quarter. XTX Topco Ltd purchased a new stake in NewAmsterdam Pharma during the 3rd quarter valued at approximately $187,000. Finally, HB Wealth Management LLC purchased a new position in NewAmsterdam Pharma during the fourth quarter worth about $224,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Insider Activity

In other NewAmsterdam Pharma news, Director James N. Topper acquired 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the transaction, the director now owns 3,013,569 shares of the company’s stock, valued at $67,775,166.81. The trade was a 0.04 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. This represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS opened at $18.21 on Thursday. The firm has a market capitalization of $2.00 billion, a PE ratio of -7.00 and a beta of -0.04. NewAmsterdam Pharma has a 1-year low of $15.19 and a 1-year high of $27.29. The business’s fifty day moving average price is $21.39 and its two-hundred day moving average price is $21.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. Equities research analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on NAMS. UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Scotiabank raised their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Thursday, February 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Needham & Company LLC lowered their target price on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma has an average rating of “Buy” and a consensus price target of $43.33.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.